Chronic Plaque Psoriasis Market Report 2025

This Chronic Plaque Psoriasis market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The chronic plaque psoriasis market size has grown strongly in recent years. It will grow from $20.79 billion in 2024 to $22.32 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth observed during the historic period can be attributed to factors such as the increasing prevalence of psoriasis, a rise in co-morbidities, favorable reimbursement policies, higher consumption of alcohol and smoking, and the growing adoption of telemedicine.

The chronic plaque psoriasis market size is expected to see strong growth in the next few years. It will grow to $29.33 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth anticipated during the forecast period can be attributed to factors such as the rising or declining global prevalence of chronic plaque psoriasis (CPP), an increase in autoimmune diseases, growth in healthcare budgets, an aging population, and the growing demand for effective treatments. Key trends expected during this period include advancements in biologic treatments, the development of oral small molecule inhibitors, the integration of digital health technologies, the rise of personalized medicine, and the introduction of biosimilars.

The rising incidence of immune system dysfunction is expected to drive growth in the chronic plaque psoriasis market. Immune system dysfunction occurs when the immune system fails to function properly, resulting in a higher risk of infections, autoimmune diseases, and cancer. Contributing factors to this increase include genetic predispositions, environmental triggers, malnutrition, chronic stress, and the growing prevalence of autoimmune diseases and infections such as HIV. Chronic plaque psoriasis treatment is essential to manage immune system dysfunction, as the immune system erroneously causes an overproduction of skin cells, leading to inflammation and plaque formation. For example, in December 2022, the National Psoriasis Foundation, a US-based nonprofit organization, reported that more than 8 million Americans are affected by psoriasis, while globally, the condition impacts 125 million people, representing 2 to 3% of the world's population. As a result, the growing cases of immune system dysfunction are fueling the expansion of the chronic plaque psoriasis market.

Leading companies in the chronic plaque psoriasis market are concentrating on developing innovative treatments, such as IL-17A and IL-17F inhibitors, to make progress in treating chronic plaque psoriasis. These inhibitors are targeted biologic therapies that block the pro-inflammatory cytokines interleukin-17A and interleukin-17F, which play a role in the immune response, helping to reduce inflammation in autoimmune conditions such as chronic plaque psoriasis. For example, in October 2023, UCB S.A., a Belgium-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved BIMZELX (bimekizumab-bkzx) for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Bimekizumab is the first psoriasis treatment specifically designed to target and inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two crucial cytokines involved in inflammation. Its approval was based on data from three Phase 3 multicenter trials - BE READY, BE VIVID, and BE SURE - which evaluated its safety and efficacy in 1,480 patients with moderate to severe plaque psoriasis.

In October 2024, Organon, a US-based healthcare company, acquired Dermavant Sciences Ltd. for an undisclosed sum. This acquisition strengthens Organon's dermatology portfolio by adding VTAMA (tapinarof) Cream, 1%, an innovative dermatologic treatment. VTAMA Cream is a novel, nonbiologic, non-steroidal topical therapy that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of mild, moderate, and severe plaque psoriasis in adults. Dermavant Sciences Ltd. is a US-based company dedicated to developing and commercializing groundbreaking therapies in the field of immunodermatology.

Major players in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Biogen Inc., UCB S.A., Dr. Reddy’s Laboratories, Innovent Biologics Inc., Dong-A ST Co. Ltd., Alumis GmbH Co KG, Zai Lab Limited, GC Cell Corporation, Affibody AB, Nimbus Therapeutics, Bio-Thera Solutions, Can-Fite Biopharma, Celgene Corporation, Kadmon Pharmaceuticals, Aldeyra Therapeutics Inc., and Arcutis Biotherapeutics.

North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chronic plaque psoriasis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the chronic plaque psoriasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chronic plaque psoriasis is a long-lasting, inflammatory skin condition marked by the development of well-defined, raised, red patches covered with silvery-white scales. These plaques commonly appear on areas such as the scalp, elbows, knees, and lower back, though they can form anywhere on the body. It is an autoimmune disorder where the immune system accelerates the turnover of skin cells, causing them to accumulate on the surface.

The primary drug classes used for treating chronic plaque psoriasis include biologics and small-molecule drugs. Biologics are advanced medications derived from living organisms that specifically target components of the immune system to treat various conditions. These drugs are available in injectable, oral, and topical forms and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies.

The chronic plaque psoriasis market research report is one of a series of new reports that provides chronic plaque psoriasis market statistics, including chronic plaque psoriasis industry global market size, regional shares, competitors with a chronic plaque psoriasis market share, detailed chronic plaque psoriasis market segments, market trends and opportunities, and any further data you may need to thrive in the chronic plaque psoriasis industry. This chronic plaque psoriasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic plaque psoriasis market consists of revenues earned by entities by providing services such as medication delivery services, customized treatment plans, and genetic and biomarker testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic plaque psoriasis market also includes sales of vitamin D analogues, combination topicals, phosphodiesterase-4 inhibitors, and janus kinase inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.